”South African pharmaceutical industry leaders are calling for stronger enforcement against unregistered weight-loss medicines, including retatrutide, an experimental drug that is not approved for general public use and remains available through clinical trials. Regulators are also reviewing medicine-compounding standards as authorities confront illegal sales, misleading online advertising and concerns about the quality and safety of products reaching consumers.”
South Africa Steps Up Efforts to Stop Illegal Weight-Loss Medicines as Patient Safety Concerns Grow
South Africa is facing renewed pressure to strengthen enforcement against illegal weight-loss medicines as pharmaceutical industry leaders, regulators and law-enforcement representatives raise concerns about the sale of unregistered products through social media, informal businesses and other channels. The developments highlight growing tensions between consumer demand for obesity treatments, the commercial opportunities surrounding new medicines and the responsibility to protect patients from products whose quality, safety and effectiveness have not been established through appropriate regulatory processes.
The issue came into focus during a pharmaceutical industry roundtable in Sandton on 14 October, with reporting published by the Mail & Guardian on 16 October. Industry representatives called for investigations, seizures and prosecutions targeting sellers of unregistered medicines. They identified retatrutide, an experimental obesity treatment developed by Eli Lilly, as a particular concern because products bearing its name are reportedly being sold outside authorised clinical trials.
Rising Demand Creates Opportunities for Illegal Medicine Sales
Demand for weight-management treatments has increased interest in medicines that affect appetite, blood sugar regulation and metabolism. Products such as Ozempic, Wegovy and Mounjaro have attracted substantial attention because of their medical applications, including diabetes management and, for certain approved products and indications, weight management.
However, the popularity of legitimate treatments has also created commercial opportunities for sellers offering cheaper alternatives or promising rapid results. Consumers encountering online advertisements may struggle to determine whether a product is authentic, legally supplied, appropriately stored or supported by reliable clinical evidence.
South African pharmaceutical industry representatives say the open promotion of unregistered products undermines confidence in the country’s medicine-control system. Pharmaceutical Task Group chair Stavros Nicolaou has called for more visible enforcement, arguing that authorities should act against sellers who openly advertise medicines without the required authorisation.
The concern extends beyond established pharmaceutical companies. Patients who purchase questionable products may face financial losses, ineffective treatment or potentially serious adverse effects. Healthcare professionals can also find themselves dealing with complications when patients cannot accurately identify what they have taken.
Retatrutide Raises Questions About Experimental Treatments
Retatrutide has attracted attention because clinical research is investigating its potential to support substantial weight loss. Unlike medicines that target fewer hormonal pathways, it acts on three receptors associated with metabolic regulation: GLP-1, GIP and glucagon.
Nevertheless, promising research findings do not make an experimental medicine suitable for unrestricted public use. Retatrutide remains investigational, and Eli Lilly has stated that it is available through its clinical trials rather than as an approved medicine for general sale.
This distinction matters because clinical trials operate under defined protocols, participant monitoring and oversight arrangements. Researchers collect evidence about effectiveness, dosage, side effects and other risks before regulators assess whether a medicine should be authorised.
Products sold outside those arrangements may not contain the substance advertised on their labels. Their concentration, purity, manufacturing conditions and storage history may also be uncertain. Without reliable quality controls, consumers cannot safely assume that a product marketed under an experimental drug’s name is genuine or equivalent to the medicine being investigated.
The presence of an experimental medicine on social media therefore does not demonstrate that it is approved, safe or suitable for a particular patient.
Regulators Face an Enforcement Challenge
The South African Health Products Regulatory Authority, known as SAHPRA, oversees the regulation of medicines and other health products. Its responsibilities include protecting public health by addressing non-compliant products and taking appropriate regulatory action.
At the October roundtable, SAHPRA regulatory compliance manager Daphney Fafudi acknowledged that regulations exist but enforcement remains challenging. She described cooperation with other institutions as important to progressing cases involving suspected illegal medicine sales.
The difficulty is partly practical. Online sellers can advertise products through multiple accounts, communicate privately with customers and arrange deliveries across geographical boundaries. Investigators may need to establish who imported a product, where it was manufactured, how it entered the country and which individuals or businesses distributed it.
Effective enforcement consequently requires coordination among medicine regulators, police, customs officials, tax authorities and professional councils. Evidence must be gathered, offences established and cases advanced through the appropriate legal procedures.
Industry representatives have urged authorities to communicate enforcement outcomes more visibly. However, sustainable progress will depend not simply on public announcements, but on investigations, lawful seizures, successful prosecutions where warranted and continued monitoring of the market.
Border Controls and Customs Investigations
The Border Management Authority has identified misleading import declarations as another concern. Commissioner and chief executive Michael Masiapato said some medicines had entered South Africa under descriptions such as cosmetics, making accurate identification and inspection particularly important.
Officials use intelligence and risk assessments to identify suspicious consignments, examine goods against import documentation and seek technical assistance from SAHPRA where necessary. Customs authorities also use electronic declarations and automated risk-assessment systems to flag potentially problematic shipments.
These controls are important because illegal medicine distribution may begin well before a product reaches an online customer or an informal retailer. Identifying suspicious imports can help investigators trace supply networks, establish the origins of products and prevent further distribution.
Nevertheless, border inspections cannot resolve every problem independently. Small consignments, personal luggage, parcel deliveries and changing shipping methods can complicate detection. Authorities must balance effective enforcement with lawful travel and trade while applying the appropriate requirements to medicines entering the country.
Cooperation between customs officials and medicine specialists is therefore essential. Customs officers can identify suspicious shipments, while regulatory experts can help establish whether products require authorisation and whether their importation or distribution complies with applicable rules.
The Risks of Unregulated Compounded Medicines
The crackdown also draws attention to pharmaceutical compounding, a legitimate practice that must be distinguished from unlawful manufacturing.
Compounding involves preparing a customised medicine for an individual patient when clinically appropriate. Under South African rules, it is not intended to provide a general route for manufacturing and marketing unregistered products at commercial scale.
On 14 October, Reuters reported that the South African Pharmacy Council and SAHPRA were developing updated standards and guidance to clarify the rules. Pharmacy Council registrar and chief executive Vincent Tlala expressed concern about pharmacies preparing products in anticipation of demand rather than for identified patients. Revised standards were expected to go before the council in February 2027, with publication targeted for March.
Clearer guidance could help legitimate practitioners understand their responsibilities while giving regulators a stronger basis for addressing non-compliant activities. It could also help patients distinguish individualised pharmaceutical care from products manufactured for broad commercial distribution without appropriate authorisation.
The distinction is especially important for injectable medicines, where sterile preparation, accurate concentrations and contamination controls are critical. Poor manufacturing conditions can introduce risks that consumers cannot identify by inspecting packaging or reading promotional claims.
Earlier Regulatory Action Highlights the Stakes
South Africa’s current concerns follow earlier enforcement action involving unregistered GLP-1 and GIP medicines.
In May 2026, SAHPRA and the Pharmacy Council announced action following an inspection at Sentra Pharmacy, operated by iDexis in Pretoria. The authorities reported serious compliance deficiencies involving products containing semaglutide, tirzepatide and combinations of the substances. Finished products found at the premises were seized, and a recall of affected products distributed through various channels was required.
The reported findings included inadequate analytical testing, deficiencies in sterile manufacturing conditions and the absence of an appropriate system for monitoring adverse drug reactions. Authorities also raised concerns about imported active pharmaceutical ingredients and promotional activities.
These findings illustrate why regulatory oversight must cover the entire medicine lifecycle. A product’s apparent popularity does not establish its quality, and a familiar ingredient name does not guarantee that an injection has been manufactured safely.
The earlier action also demonstrates that South Africa already has legal and regulatory mechanisms for addressing suspected unlawful manufacturing. The current debate centres on improving enforcement, closing practical gaps and ensuring that rules are applied consistently.
What Patients Should Know Before Buying Weight-Loss Medicines
Healthcare professionals advise patients to approach products advertised as powerful or rapid weight-loss solutions with caution. Claims of dramatic results, unusually low prices, guaranteed outcomes or access to experimental treatments outside formal research settings deserve particular scrutiny.
Consumers should seek advice from qualified healthcare professionals before beginning treatment. A clinician can assess relevant medical conditions, review current medicines and discuss appropriate treatment options based on individual circumstances.
Patients should also verify that medicines are legally authorised and obtained through legitimate healthcare channels. They should not assume that a product is genuine merely because a seller operates a professional-looking website, uses medical terminology or claims to work with healthcare providers.
Anyone who has used a suspicious injectable product and experiences concerning symptoms should seek prompt medical assistance and tell the treating professional what was taken, when it was used and where it was obtained. Packaging, receipts and product details may help clinicians assess possible exposure.
People should not stop prescribed diabetes treatment or replace an established medicine with an online alternative without professional advice. Unsupervised changes can disrupt blood glucose control and create additional health risks.
Protecting Patients While Preserving Access to Treatment
The enforcement debate also raises broader questions about affordability and access. Legitimate weight-management medicines may be expensive, while patients living with obesity or diabetes may need sustained clinical support.
When effective treatment appears financially inaccessible, some consumers may become more willing to consider unverified alternatives. This does not justify illegal sales, but it highlights why enforcement should be accompanied by accessible medical advice, transparent information and appropriate treatment options.
Healthcare providers can help by explaining the differences between approved medicines, authorised indications, experimental treatments and compounded preparations. Public education should also address misleading claims and make it easier for consumers to report suspicious products.
Meanwhile, policymakers must consider how medicine regulation, procurement, competition and supply security affect patient access. Strong safeguards should protect consumers without unnecessarily obstructing legitimate pharmaceutical innovation or properly supervised individualised care.
Government and Industry Under Pressure to Deliver Results
President Cyril Ramaphosa has also mandated a government-business task force to address challenges facing South Africa’s pharmaceutical sector. According to Business Day’s reporting on 13 October, its priorities include medicine-pricing regulation, preferential local procurement, SAHPRA-related regulatory matters and improved use of data for policy decisions.
The task force’s work provides an opportunity to examine the relationship between medicine availability, local manufacturing, regulatory effectiveness and patient affordability. However, wider industrial reforms and investigations into illegal products are distinct responsibilities; progress in one area cannot substitute for action in the other.
The immediate challenge is to ensure that medicines supplied to the public meet appropriate legal and quality requirements. This requires practical cooperation, adequate investigative capacity, clear rules and proportionate enforcement based on evidence.
Conclusion: Patient Safety Must Remain the Priority
South Africa’s renewed focus on illegal weight-loss medicines highlights the risks created when demand for promising treatments outpaces public understanding and regulatory control.
The central issue is not whether scientific research into obesity treatment should continue. Rather, it is whether consumers can trust that medicines offered for sale are genuine, appropriately assessed and supplied through lawful channels.
Authorities have signalled that they intend to strengthen cooperation and clarify compounding requirements. Industry representatives are demanding more visible enforcement, while patients need understandable information and access to qualified healthcare professionals.
The effectiveness of these efforts will ultimately depend on measurable results: fewer unlawful products reaching consumers, stronger investigation of suspected offences, better public awareness and reliable access to legitimate treatment.
For patients considering weight-loss medication, the safest course is to consult a qualified healthcare professional and avoid experimental or unregistered products sold outside authorised channels. For regulators, the priority is to ensure that innovation and commercial demand never come at the expense of patient safety.
